admin, Author at Généthon - Page 2 of 10

Genethon Announces Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety

September 12, 2024

Marking World Duchenne Muscular Dystrophy Day, Genethon Reaffirms Its Commitment to Helping Patientsfor 35 years and Provides an Update on Its PromisingGene Therapy Drug Candidate for This Fatal Disease

September 6, 2024

Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne muscular dystrophy

December 14, 2022

Téléthon 2022: Benjamin, a hope for families thanks to clinical trials

November 21, 2022

Telethon 2022: for Lucie, “a real opportunity, thanks to advances in research”

November 21, 2022

Genethon’s Latest Research, Including Advances in Gene Editing and AAV Delivery Vectors for Gene Therapy, to be Featured at European Society for Gene and Cell Therapy, Oct. 11-14, 2022

October 11, 2022

Publication: Genethon helps identify two vectors optimized for muscles via a European H2020 program

October 5, 2022

First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9

September 26, 2022

Genethon to Present Its Latest Gene Therapy Research Advancements in Neuromuscular Diseases at the International Myology 2022 Congress

September 12, 2022